Mukhopadhyay, Suman http://orcid.org/0000-0002-4658-1942
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
McCormick, Frank http://orcid.org/0000-0002-6619-7120
Funding for this research was provided by:
Frederick National Laboratory for Cancer Research (HHSN261200800001E, HHSN261200800001E, HHSN261200800001E)
Article History
Received: 9 November 2020
Accepted: 10 February 2021
First Online: 24 March 2021
Competing interests
: The authors are aware of no direct conflicts with the topic of the paper; however, M.G.V.H. is a scientific advisory board member for Agios Pharmaceuticals, Aeglea Biotherapetics, iTeos Therapeutics, Faeth Therapeutics and Auron Therapeutics. F.M. is a consultant for the following companies: Amgen, Daiichi, Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, PellePharm, Pfizer, PMV Pharma and Quanta Therapeutics. F.M. is a consultant and co-founder for the following companies (with ownership interest including stock options): BridgeBio, DNAtrix, Olema Pharmaceuticals and Quartz. F.M. is the scientific director of the NCI RAS Initiative at the Frederick National Laboratory for Cancer Research/Leidos Biomedical Research. None of these affiliations represents a conflict of interest with respect to this paper.